116 related articles for article (PubMed ID: 21170498)
1. [The expression of a novel estrogen receptor, GPR30, in epithelial ovarian carcinoma and its correlation with MMP-9].
Liu HD; Yan Y; Cao XF; Tan PZ; Wen HX; Lv CM; Li XM; Liu GY
Sheng Li Xue Bao; 2010 Dec; 62(6):524-8. PubMed ID: 21170498
[TBL] [Abstract][Full Text] [Related]
2. Transmembrane estrogen receptor GPR30 is more frequently expressed in malignant than benign ovarian endometriotic cysts and correlates with MMP-9 expression.
Long L; Cao Y; Tang LD
Int J Gynecol Cancer; 2012 May; 22(4):539-45. PubMed ID: 22495744
[TBL] [Abstract][Full Text] [Related]
3. [Correlation between bacterial L-form infection, expression of HIF-1α/MMP-9 and vasculogenic mimicry in epithelial ovarian cancer].
Yu L; Wu SW; Zhou L; Song WQ
Sheng Li Xue Bao; 2012 Dec; 64(6):657-65. PubMed ID: 23258329
[TBL] [Abstract][Full Text] [Related]
4. GPR30 predicts poor survival for ovarian cancer.
Smith HO; Arias-Pulido H; Kuo DY; Howard T; Qualls CR; Lee SJ; Verschraegen CF; Hathaway HJ; Joste NE; Prossnitz ER
Gynecol Oncol; 2009 Sep; 114(3):465-71. PubMed ID: 19501895
[TBL] [Abstract][Full Text] [Related]
5. Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.
Zhu CX; Xiong W; Wang ML; Yang J; Shi HJ; Chen HQ; Niu G
J Int Med Res; 2018 Feb; 46(2):723-731. PubMed ID: 29239277
[TBL] [Abstract][Full Text] [Related]
6. The G-protein coupled estrogen receptor (GPER/GPR30) is a gonadotropin receptor dependent positive prognosticator in ovarian carcinoma patients.
Heublein S; Mayr D; Vrekoussis T; Friese K; Hofmann SS; Jeschke U; Lenhard M
PLoS One; 2013; 8(8):e71791. PubMed ID: 23951246
[TBL] [Abstract][Full Text] [Related]
7. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
Sakata K; Shigemasa K; Nagai N; Ohama K
Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
[TBL] [Abstract][Full Text] [Related]
8. The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma.
Gorovetz M; Baekelandt M; Berner A; Trope' CG; Davidson B; Reich R
Gynecol Oncol; 2006 Dec; 103(3):831-40. PubMed ID: 16919315
[TBL] [Abstract][Full Text] [Related]
9. G Protein-Coupled Estrogen Receptor Correlates With Dkk2 Expression and Has Prognostic Impact in Ovarian Cancer Patients.
Fraungruber P; Kaltofen T; Heublein S; Kuhn C; Mayr D; Burges A; Mahner S; Rathert P; Jeschke U; Trillsch F
Front Endocrinol (Lausanne); 2021; 12():564002. PubMed ID: 33679613
[TBL] [Abstract][Full Text] [Related]
10. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
Meng Q; Duan P; Li L; Miao Y
Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
[TBL] [Abstract][Full Text] [Related]
11. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
12. Over-Expression of TBL1XR1 Indicates Poor Prognosis of Serous Epithelial Ovarian Cancer.
Ma M; Yu N
Tohoku J Exp Med; 2017 Mar; 241(3):239-247. PubMed ID: 28344213
[TBL] [Abstract][Full Text] [Related]
13. EphA8 is a prognostic marker for epithelial ovarian cancer.
Liu X; Xu Y; Jin Q; Wang W; Zhang S; Wang X; Zhang Y; Xu X; Huang J
Oncotarget; 2016 Apr; 7(15):20801-9. PubMed ID: 26989075
[TBL] [Abstract][Full Text] [Related]
14. Expression and correlation of CD44v6, vascular endothelial growth factor, matrix metalloproteinase-2, and matrix metalloproteinase-9 in Krukenberg tumor.
Lou G; Gao Y; Ning XM; Zhang QF
World J Gastroenterol; 2005 Aug; 11(32):5032-6. PubMed ID: 16124061
[TBL] [Abstract][Full Text] [Related]
15. [Expression of hSef and FGF-2 in epithelial ovarian tumor].
Feng QL; Shi HR; Qiao LJ; Zhao J
Zhonghua Zhong Liu Za Zhi; 2011 Oct; 33(10):770-4. PubMed ID: 22335910
[TBL] [Abstract][Full Text] [Related]
16. [Expressions of ZEB2 and C-myc in epithelial ovarian cancer and their clinical significance].
Wang Q; Jiang H; Deng X; Fang W; Guo S
Nan Fang Yi Ke Da Xue Xue Bao; 2015 Dec; 35(12):1765-9. PubMed ID: 26714913
[TBL] [Abstract][Full Text] [Related]
17. [Expression of KiSS-1, matrix metalloproteinase-9, nuclear factor-kappaBp65 in ovarian tumour].
Gao GL; Liu LD; Zou XS; Chen WX
Zhonghua Fu Chan Ke Za Zhi; 2007 Jan; 42(1):34-8. PubMed ID: 17331419
[TBL] [Abstract][Full Text] [Related]
18. Upregulated CDK16 Expression in Serous Epithelial Ovarian Cancer Cells.
Zhou Q; Yu Y
Med Sci Monit; 2015 Nov; 21():3409-14. PubMed ID: 26546806
[TBL] [Abstract][Full Text] [Related]
19. The correlation between immunohistochemical expression of MMP-2 and the prognosis of epithelial ovarian cancer.
Ekinci T; Ozbay PO; Yiğit S; Yavuzcan A; Uysal S; Soylu F
Ginekol Pol; 2014 Feb; 85(2):121-30. PubMed ID: 24745158
[TBL] [Abstract][Full Text] [Related]
20. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
Zhang MZ; Qiao YH; Suo ZH
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
